CLINICAL TRIALS PROFILE FOR BIS-CHOLINE TETRATHIOMOLYBDATE
✉ Email this page to a colleague
Clinical Trials for Bis-choline tetrathiomolybdate
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04422431 ↗ | Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 | Active, not recruiting | Alexion Pharmaceuticals | Phase 2 | The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or zinc). In the Treatment Period, efficacy and safety of ALXN1840 will be assessed at Week 48. |
| NCT04526197 ↗ | Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. | Completed | Alexion Pharmaceuticals | Phase 1 | This was a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of celecoxib, a sensitive cytochrome P450 2C9 (CYP2C9) substrate, in healthy male and female participants. The safety and tolerability of ALXN1840 were determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via total molybdenum with the coadministration of celecoxib. |
| NCT04526210 ↗ | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | Completed | Alexion Pharmaceuticals | Phase 1 | This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female participants. The safety and tolerability of ALXN1840 will be determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via total molybdenum with the coadministration of bupropion. |
| NCT04560816 ↗ | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | Enrolling by invitation | ERT: Clinical Trial Technology Solutions | Phase 1 | This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control. |
| NCT04560816 ↗ | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | Enrolling by invitation | PPD | Phase 1 | This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control. |
| NCT04560816 ↗ | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | Enrolling by invitation | Alexion Pharmaceuticals | Phase 1 | This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Bis-choline tetrathiomolybdate
Condition Name
Clinical Trial Locations for Bis-choline tetrathiomolybdate
Trials by Country
Clinical Trial Progress for Bis-choline tetrathiomolybdate
Clinical Trial Phase
Clinical Trial Sponsors for Bis-choline tetrathiomolybdate
Sponsor Name
